It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or
consider using other browsers such as Chrome, Firefox or Safari.
AIN457 Phase 3 clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Ankylosing Spondylitis or Non-radiographic Axial SpondyloArthritis. Phase III clinical study.
To learn the definitions of some words used in clinical trial descriptions, please watch the Definitions video from our Understanding Clinical Trials series.
ClinicalTrials.gov Identifier: NCT04156620 | Novartis reference number: CAIN457P12301 | Last updated on: July 24, 2020
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
If living with AS or nr-axSpA is causing you constant pain and disrupting your life, even with current treatment, this trial may be the first step towards helping find a treatment for the long-term relief you deserve.
If you or someone you care about is living with AS or nr-axSpA, Novartis invites you to take part in a new clinical trial for an IV form of secukinumab. To potentially help patients get faster and longer-lasting relief from this condition, we are looking for people who have been diagnosed with AS or nr-axSpA to participate in the development and delivery of this new medicine. We are seeking 500 participants globally, 90 in the United States.
We are working to develop an IV version of the medicine that might:
Click here to watch all of our Understanding Clinical Trials videos.
To demonstrate the efficacy, safety, and tolerability of an IV regimen of secukinumab compared to placebo in subjects with active nr-axSpA or AS at Week 16 despite current or previous nonsteroidal anti-inflammatory drug (NSAID), disease-modifying anti-rheumatic drug (DMARD), and/or anti-tumor necrosis factor (TNF) therapy. In addition, to further support efficacy and safety of an IV regimen, data will be collected for up to 52 weeks of treatment. Efficacy and safety data may also be used to support the registration of IV secukinumab in the United States and other countries for treatment of subjects with active axSpA.
Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis
18 Years and Older (Adult, Older Adult)
December 11, 2019
If you wish to participate in the trial, you must meet the following requirements:
Your doctor can also help you to determine if you qualify by performing the required diagnostic tests.
For a complete list of inclusion and exclusion criteria, please click here.
This study will consist of 4 periods totalling up to 70 weeks:
You will not be charged for participation or early exit from the trial and can drop out at any time.
The primary purpose of the study is to examine the trial medicine’s effectiveness vs a placebo. You will be placed in 1 of 2 groups at random, which will determine the type of study treatment you receive.
You will not be treated with a placebo beyond week 16 if you’re randomized for Group 2.
To see if you qualify for the study, fill out the pre-screener here and a study representative may contact you. We encourage you to speak with your doctor before completing the questionnaire. You may be referred to a trial location near you, where a physical exam will be performed before determining your eligibility for the trial. If you find that you’re not qualified to participate in the trial, we encourage you to work with your doctor to find other options for AS or nr-axSpA symptom relief.